Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.

MLA

Massari, Francesco, et al. “Global Real-World Experiences with Pembrolizumab in Advanced Urothelial Carcinoma after Platinum-Based Chemotherapy: The ARON-2 Study.” Cancer Immunology, Immunotherapy, vol. 73, no. 6, June 2024, pp. 1–13. EBSCOhost, https://doi.org/10.1007/s00262-024-03682-w.

APA

Massari, F., Santoni, M., Takeshita, H., Okada, Y., Tapia, J. C., Basso, U., Maruzzo, M., Scagliarini, S., Büttner, T., Fornarini, G., Myint, Z. W., Galli, L., Souza, V. C., Pichler, R., De Giorgi, U., Gandur, N., Lam, E. T., Gilbert, D., Popovic, L., & Grande, E. (2024). Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer Immunology, Immunotherapy, 73(6), 1–13. https://doi.org/10.1007/s00262-024-03682-w

Chicago

Massari, Francesco, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Umberto Basso, Marco Maruzzo, et al. 2024. “Global Real-World Experiences with Pembrolizumab in Advanced Urothelial Carcinoma after Platinum-Based Chemotherapy: The ARON-2 Study.” Cancer Immunology, Immunotherapy 73 (6): 1–13. doi:10.1007/s00262-024-03682-w.